BOSTON (MedPage Today) -- An investigational oral drug for multiple sclerosis with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer effects on cardiac function than the earlier drug. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment